We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

88 hedge funds and large institutions have $822M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 22

3% more capital invested

Capital invested by funds: $795M → $822M (+$27.2M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 8988 (-1)

Holders
88
Holders Change
-1
Holders Change %
-1.12%
% of All Funds
2.01%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
15
Increased
35
Reduced
22
Closed
16
Calls
$352K
Puts
Net Calls
+$352K
Net Calls Change
+$352K
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$5.43M +$936K +25,343 +22%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$5.41M +$294K +7,953 +6%
FI
28
Fosun International
China
$4.96M +$4.73M +128,037 New
Axa
29
Axa
France
$4.87M +$1.61M +43,668 +53%
SFM
30
Sphera Funds Management
Israel
$4.26M +$628K +17,002 +18%
SA
31
Sunesis Advisors
Kansas
$3.73M
Millennium Management
32
Millennium Management
New York
$3.21M +$2.05M +55,464 +203%
EI
33
EAM Investors
California
$3.12M -$164K -4,446 -5%
Charles Schwab
34
Charles Schwab
California
$2.74M +$376K +10,188 +17%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2.57M +$368K +9,966 +18%
IBT
36
International Biotechnology Trust
United Kingdom
$2.29M
Invesco
37
Invesco
Georgia
$1.75M +$1.67M +45,174 New
PPA
38
Parametric Portfolio Associates
Washington
$1.68M +$340K +9,209 +27%
Squarepoint
39
Squarepoint
New York
$1.29M +$193K +5,221 +19%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$1.19M -$497K -13,444 -30%
NC
41
Nexthera Capital
New York
$1.19M -$3.66M -99,178 -76%
Federated Hermes
42
Federated Hermes
Pennsylvania
$1.11M +$1.06M +28,756 New
EGI
43
EAM Global Investors
California
$1.09M
Swiss National Bank
44
Swiss National Bank
Switzerland
$995K
Ameriprise
45
Ameriprise
Minnesota
$961K -$157K -4,259 -15%
Citigroup
46
Citigroup
New York
$959K +$871K +23,569 +1,999%
SO
47
STRS Ohio
Ohio
$704K +$584K +15,800 +658%
EDRIA
48
Edmonds Duncan Registered Investment Advisors
Kansas
$687K
TA
49
Teachers Advisors
New York
$665K +$78.3K +2,119 +14%
TCIM
50
TIAA CREF Investment Management
New York
$586K -$26K -703 -4%

DCPH Hedge Fund Activity: Q3 2018 in Review

88 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2018, worth a combined $822M — up 3.4% from $795M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of DCPH and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 35 added.

The largest buyer was State Street, adding an estimated $16.2M. The largest seller was Viking Global Investors, cutting an estimated $24.5M.

  • 88 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2018, down from 89 in Q2 2018.
  • Funds reported $822M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 3.4% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 16 closed out, a net change of -1 holder.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was State Street, an estimated $16.2M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Viking Global Investors, an estimated $24.5M sold.

Based on aggregated 13F filings for Q3 2018.